Assignors: Vega, Julio César Status Active legal-status Critical Current Anticipated expiration legal-status Critical Links ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US202063035982P external-priority Application filed by Amcyte Pharma Inc filed Critical Amcyte Pharma Inc Priority to US16/900,488 priority Critical patent/US11013687B1/en Priority to US17/321,729 priority patent/US20210386667A1/en Application granted granted Critical Publication of US11013687B1 publication Critical patent/US11013687B1/en Priority to PCT/US2021/035611 priority patent/WO2021252254A1/en Assigned to Amcyte Pharma Inc. Original Assignee Amcyte Pharma Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Application number US16/900,488 Inventor Julio César Vega Current Assignee (The listed assignees may be inaccurate.
#Iota carrageenan covid pdf
Google Patents Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2ĭownload PDF Info Publication number US11013687B1 US11013687B1 US16/900,488 US202016900488A US11013687B1 US 11013687 B1 US11013687 B1 US 11013687B1 US 202016900488 A US202016900488 A US 202016900488A US 11013687 B1 US11013687 B1 US 11013687B1 Authority US United States Prior art keywords solution nasal xylitol iota carrageenan carrageenan Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US11013687B1 - Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2 US11013687B1 - Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2
0 kommentar(er)
